RESUMO
Coronavirus disease 2019 (COVID-19) has affected a broad demographics, eliciting a more significant effect on specific groups such as males, African Americans, and Hispanic minorities. Treatment of COVID-19 often requires antiviral drugs or monoclonal antibodies. However, immunotherapies such as mesenchymal stem cells and mesenchymal stem cells-derived exosomal vesicles should be evaluated as treatment options for COVID-19. Mesenchymal stem cell therapy offers regenerative, anti-inflammatory, and immunomodulatory properties that can speed up the recovery from COVID-19. Mesenchymal stem cell therapy can also benefit COVID-19 patients who suffer from strokes, as COVID-19 increases the risk of strokes due to increased cytokines and clotting factors. Most stroke cases that occur in COVID-19 patients are ischemic strokes. Therefore, with the help of mesenchymal stem cell therapy and mesenchymal stem cells-derived exosomes, COVID-19-induced stroke patients might benefit from dual-ended treatment. The objective of this review was to discuss COVID-19 and stroke incidence and the available treatment options.
RESUMO
Alzheimers's disease is one of the alarming neurodegenerative disease and it is of global concern.The hallmarks of the disease are the amyloid beta (Aß) aggregation and presence of neurofibrillary tangles (NFTs). The interaction of Aß with macromolecular targets affects the normal cellular functions. The amyloid peptide interaction with cellular surfaces may trigger the intracellular cascades of signalling. Interaction of Aß with mitochondria leads to the generation of free radicals. Many studies have suggested the involvement of mitochondrial dysfunction in Alzheimer's disease. Melatonin prevents mitochondria stress and by means of activating the antioxidant systems it protects the death of neurons. Although the study have been already conducted on Aß42 infused or injury induced animal models but till date there is no reports of such studies on transgenic model of Drosophila melanogaster. In the present study, we have taken UAS/Gal4 system for the development of transgenic flies that overexpress Aß42 in the brain of Drosophila. With the help of these transgenic flies we have analyse different experiments like behavioural parameters, oxidative stress parameters and protein expression through western blotting in the presence of melatonin. We have found that melatonin significantly ameliorated the toxicity caused by the Aß42 overexpression. Thus the present study could be beneficial to find out the role of melatonin in transgenic flies overexpressing human Aß42.
